NO324064B1 - Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav - Google Patents
Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav Download PDFInfo
- Publication number
- NO324064B1 NO324064B1 NO19995843A NO995843A NO324064B1 NO 324064 B1 NO324064 B1 NO 324064B1 NO 19995843 A NO19995843 A NO 19995843A NO 995843 A NO995843 A NO 995843A NO 324064 B1 NO324064 B1 NO 324064B1
- Authority
- NO
- Norway
- Prior art keywords
- vwf
- pro
- propeptide
- preparation
- pharmaceutical
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 208000015294 blood coagulation disease Diseases 0.000 claims abstract description 4
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 185
- 102100036537 von Willebrand factor Human genes 0.000 claims description 184
- 229960001134 von willebrand factor Drugs 0.000 claims description 184
- 230000000694 effects Effects 0.000 claims description 23
- 241000700605 Viruses Species 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 12
- 230000007017 scission Effects 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 229920001436 collagen Polymers 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- 230000023555 blood coagulation Effects 0.000 claims description 7
- 229960000182 blood factors Drugs 0.000 claims description 7
- 230000002779 inactivation Effects 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 208000031220 Hemophilia Diseases 0.000 claims description 5
- 208000009292 Hemophilia A Diseases 0.000 claims description 5
- 230000023597 hemostasis Effects 0.000 claims description 5
- 108010054218 Factor VIII Proteins 0.000 claims description 4
- 102000001690 Factor VIII Human genes 0.000 claims description 4
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 claims description 4
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 108020004511 Recombinant DNA Proteins 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 229960000301 factor viii Drugs 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 2
- 229940124135 Factor VIII inhibitor Drugs 0.000 claims description 2
- 108010061932 Factor VIIIa Proteins 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 2
- 208000031814 IgA Vasculitis Diseases 0.000 claims description 2
- 208000009567 Neonatal Alloimmune Thrombocytopenia Diseases 0.000 claims description 2
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 claims description 2
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 claims description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000030372 neonatal thrombocytopenia Diseases 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000009931 harmful effect Effects 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 27
- 108090000190 Thrombin Proteins 0.000 description 21
- 229960004072 thrombin Drugs 0.000 description 21
- 210000001772 blood platelet Anatomy 0.000 description 15
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000027276 Von Willebrand disease Diseases 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 231100000319 bleeding Toxicity 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 200000000007 Arterial disease Diseases 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100035233 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000035868 Vascular inflammations Diseases 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000000729 antidote Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 108010083526 asialo-von Willebrand Factor Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229940124280 l-arginine Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 101800001769 von Willebrand antigen 2 Proteins 0.000 description 1
- 102400000842 von Willebrand antigen 2 Human genes 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0091797A AT405485B (de) | 1997-05-28 | 1997-05-28 | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
| PCT/EP1998/003090 WO1998053848A1 (fr) | 1997-05-28 | 1998-05-26 | Preparation pharmaceutique a base de propeptide de facteur de von willebrand |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO995843D0 NO995843D0 (no) | 1999-11-29 |
| NO995843L NO995843L (no) | 2000-01-27 |
| NO324064B1 true NO324064B1 (no) | 2007-08-06 |
Family
ID=3502803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19995843A NO324064B1 (no) | 1997-05-28 | 1999-11-29 | Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7005502B1 (fr) |
| EP (1) | EP0977584B1 (fr) |
| JP (1) | JP4335978B2 (fr) |
| AT (2) | AT405485B (fr) |
| AU (1) | AU744643B2 (fr) |
| CA (1) | CA2288737A1 (fr) |
| DE (1) | DE69802918T2 (fr) |
| ES (1) | ES2168766T3 (fr) |
| NO (1) | NO324064B1 (fr) |
| WO (1) | WO1998053848A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4663837B2 (ja) * | 1999-12-24 | 2011-04-06 | 一般財団法人化学及血清療法研究所 | 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物 |
| US7033994B2 (en) | 1999-12-24 | 2006-04-25 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy |
| BRPI0519562A2 (pt) | 2004-12-27 | 2009-01-27 | Baxter Int | construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| CA2647314A1 (fr) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Facteur viii pegyle |
| KR101643277B1 (ko) * | 2007-12-28 | 2016-07-28 | 박스알타 인코퍼레이티드 | 재조합 ｖｗｆ 제제 |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| ES2298096B1 (es) | 2008-01-08 | 2009-01-01 | Grifols, S.A. | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
| CA2740919A1 (fr) | 2008-10-21 | 2010-04-29 | Baxter International Inc. | Formulations de vwf recombinant lyophilise |
| CA2741634A1 (fr) * | 2008-10-27 | 2010-06-03 | Baxter International Inc. | Modeles de purpura thrombopenique thrombotique et procedes d'utilisation de ceux-ci |
| CN106008697B (zh) | 2009-08-20 | 2020-08-04 | 百深公司 | 纯化vwf以增加非-脂质包封的病毒的去除 |
| US20110150843A1 (en) * | 2009-10-30 | 2011-06-23 | National Institute Of Immunology | Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells |
| US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| WO2017055072A1 (fr) | 2015-10-02 | 2017-04-06 | Asml Netherlands B.V. | Procédé et appareil de métrologie, programme informatique et système lithographique |
| US10632176B2 (en) | 2017-07-07 | 2020-04-28 | Baxalta Incorporated | Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF |
| WO2019010496A1 (fr) | 2017-07-07 | 2019-01-10 | Baxalta Incorporated | Traitement de patients atteints d'une forme grave de la maladie de von willebrand subissant une intervention chirurgicale non urgente par l'administration de vwf recombiné |
| BR112020019057A2 (pt) | 2018-03-21 | 2020-12-29 | Baxalta Incorporated | Método para obter uma composição, e, composição farmacêutica. |
| JP2022524291A (ja) | 2019-02-01 | 2022-05-02 | 武田薬品工業株式会社 | 組換えＶＷＦ（ｒＶＷＦ）を使用する予防治療法 |
| US20220401524A1 (en) | 2019-09-11 | 2022-12-22 | Takeda Pharmaceutical Company Limited | Methods of treatment related to complexes of von willebrand factor and complement c1q |
| US20230398188A1 (en) | 2020-02-04 | 2023-12-14 | Takeda Pharmaceutical Company Limited | Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT350726B (de) | 1976-08-30 | 1979-06-11 | Immuno Ag | Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma |
| AT368883B (de) | 1980-07-22 | 1982-11-25 | Immuno Ag | Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen |
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| AT378005B (de) | 1983-08-20 | 1985-06-10 | Linde Ag | Verfahren zum desoxidieren von metallschmelzen |
| AT389815B (de) | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
| US5198349A (en) * | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| AT390560B (de) | 1986-05-30 | 1990-05-25 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern |
| US5849536A (en) * | 1990-03-02 | 1998-12-15 | Bio-Technology General Corp. | Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same |
| FR2673632A1 (fr) * | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
| AT402891B (de) | 1991-06-20 | 1997-09-25 | Immuno Ag | Verfahren zur herstellung eines inaktivierten blutproduktes |
| AT398079B (de) | 1991-11-04 | 1994-09-26 | Immuno Ag | Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung |
| WO1994013329A1 (fr) | 1992-12-16 | 1994-06-23 | Immuno Aktiengesellschaft | Procede de preparation de compositions biologiques exemptes de virus |
| AT402788B (de) | 1993-08-03 | 1997-08-25 | Immuno Ag | Virussichere blutgerinnungsfaktor xiii-präparation |
| JPH07330797A (ja) * | 1994-05-31 | 1995-12-19 | Sumitomo Metal Ind Ltd | 新規細胞接着活性ペプチド |
| DE4437544A1 (de) * | 1994-10-20 | 1996-04-25 | Behringwerke Ag | Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika |
| US6068838A (en) | 1996-04-29 | 2000-05-30 | Baxter Aktiengesellschaft | Purified multimerase |
| AT404359B (de) | 1996-04-29 | 1998-11-25 | Immuno Ag | Gereinigte multimerase |
| AT404554B (de) | 1996-04-29 | 1998-12-28 | Immuno Ag | Pharmazeutische präparation |
-
1997
- 1997-05-28 AT AT0091797A patent/AT405485B/de not_active IP Right Cessation
-
1998
- 1998-05-26 US US09/424,498 patent/US7005502B1/en not_active Expired - Lifetime
- 1998-05-26 DE DE69802918T patent/DE69802918T2/de not_active Expired - Lifetime
- 1998-05-26 JP JP50022099A patent/JP4335978B2/ja not_active Expired - Lifetime
- 1998-05-26 WO PCT/EP1998/003090 patent/WO1998053848A1/fr active IP Right Grant
- 1998-05-26 CA CA002288737A patent/CA2288737A1/fr not_active Abandoned
- 1998-05-26 EP EP98929378A patent/EP0977584B1/fr not_active Expired - Lifetime
- 1998-05-26 AU AU79156/98A patent/AU744643B2/en not_active Expired
- 1998-05-26 AT AT98929378T patent/ATE210455T1/de active
- 1998-05-26 ES ES98929378T patent/ES2168766T3/es not_active Expired - Lifetime
-
1999
- 1999-11-29 NO NO19995843A patent/NO324064B1/no not_active IP Right Cessation
-
2005
- 2005-09-01 US US11/218,406 patent/US7557188B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69802918T2 (de) | 2003-04-10 |
| JP2001527579A (ja) | 2001-12-25 |
| NO995843D0 (no) | 1999-11-29 |
| JP4335978B2 (ja) | 2009-09-30 |
| NO995843L (no) | 2000-01-27 |
| CA2288737A1 (fr) | 1998-12-03 |
| DE69802918D1 (de) | 2002-01-24 |
| ATE210455T1 (de) | 2001-12-15 |
| ES2168766T3 (es) | 2002-06-16 |
| US20060003921A1 (en) | 2006-01-05 |
| US7557188B2 (en) | 2009-07-07 |
| ATA91797A (de) | 1999-01-15 |
| AU7915698A (en) | 1998-12-30 |
| AU744643B2 (en) | 2002-02-28 |
| AT405485B (de) | 1999-08-25 |
| WO1998053848A1 (fr) | 1998-12-03 |
| EP0977584B1 (fr) | 2001-12-12 |
| EP0977584A1 (fr) | 2000-02-09 |
| US7005502B1 (en) | 2006-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7557188B2 (en) | Methods of treating blood coagulation disorders using a pharmaceutical preparation comprising vWF propeptide | |
| US5877152A (en) | Method for isolation of highly pure von Willebrand Factor | |
| Koedam et al. | Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. | |
| KR100303872B1 (ko) | 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법 | |
| EP0719154B1 (fr) | Facteur viii active utilise comme agent therapeutique et procede permettant de traiter une deficience en facteur viii | |
| De Bosch et al. | Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I) | |
| JPH09221432A (ja) | フォンビルブラント因子を含む医薬調製物 | |
| US5484890A (en) | Antihemophilic factor stabilization | |
| EP0907724B1 (fr) | Multimerase purifiee | |
| JP2005511038A (ja) | 第ｖｉｉｉ因子ｃ２ドメインのバリアント | |
| US20140193441A1 (en) | Method of Administering Porcine B-domainless fVIII | |
| Mitchell et al. | Cleavage of protein S by a platelet membrane protease. | |
| CA2301514A1 (fr) | Preparations deshydratees possedant une activite biologique ou therapeutique | |
| US5091363A (en) | Agent for the therapy of factor viii-resistant hemophilia a, and a process for the preparation thereof | |
| US20240189398A1 (en) | Liquid composition comprising factor viii or factor viii/von willebrand factor complex | |
| Turecek et al. | Factor eight inhibitor bypassing activity | |
| Chung et al. | The antithrombotic properties of human prothrombin fragment 1.2 in mice | |
| AU8723198A (en) | Dried biologically or therapeutically active preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BAXALTA INCORPORATED, CH |
|
| MK1K | Patent expired |